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Abstract. The potential of cell-based therapies in diseases 
involving ischemia-reperfusion is greatly hampered by the 
excessive loss of administered cells in the harsh and oxidative 
environment where these cells are supposed to act. Therefore, 
we investigated if inhibition of poly(ADP-ribose) polymerase 
(PARP) in the therapeutically added cells would lead to their 
increased viability and, subsequently, to an enhanced effect 
in an in vitro simulated ischemia-reperfusion (I-R) setting. 
Ischemic conditions were simulated by oxygen and glucose 
deprivation for 160 min using H9c2 rat cardiomyoblast cells. 
After 30 min of reperfusion, these cells received 4 types of 
treatments: no added cells (I-R model), fluorescently labeled 
(Vybrant DiD) therapeutic H9c2 cells with vehicle (H9c2) 
or PARP inhibitor (10 µM or 100 µM PJ34) pretreatment. 
We assessed viability (live, apoptotic and necrotic) of both 
‘postischemic’ and therapeutic cells with flow cytometric 
analysis using calcein-AM/ethidium homodimer-2 fluorescent 
staining after 24 h of co-culture. Further measurements on 
necrosis and metabolic activity were performed using lactate 
dehydrogenase (LDH) release and resazurin based assays. 
The percentage of surviving therapeutic cells increased 
significantly with PARP inhibition (untreated, 52.02±5.01%; 
10 µM PJ34, 63.38±4.50%; 100 µM PJ34, 64.99±3.47%). The 
percentage of necrotic cells decreased in a similar manner 
(untreated, 37.23±4.40%; 10 µM PJ34, 26.83±3.49%; 100 µM 
PJ34, 24.96±2.43%). Notably, the survival of the cells that 
suffered I-R injury was also significantly higher when 
treated with PARP-inhibited therapeutic cells (I-R model, 
36.44±5.05%; H9c2, 42.81±5.11%; 10 µM PJ34, 52.07±5.80%; 
100 µM PJ34, 54.95±5.55%), while necrosis was inhibited 
(I-R model, 43.64±4.00%; H9c2, 37.29±4.55%; 10 µM PJ34, 
30.18±4.60%; 100 µM PJ34, 25.52±3.47%). In subsequent 
experiments, PARP inhibition decreased LDH-release of the 
observed combined cell population and enhanced the meta-
bolic activity. Thus, our results suggest that pretreating the 
therapeutically added cells with a PARP inhibitor could be 
beneficial in the setting of cell-based therapies.
Introduction
Regenerating the heart through cell transplantation is a 
promising novel approach in the therapy of myocardial 
infarct and various investigations have provided evidence that 
this approach has indeed the potential to improve the func-
tionality of the injured heart (1,2). However, a meta-analysis 
with nearly a thousand patients concluded that bone marrow 
derived cell transplantation resulted in only a modest 3.66% 
improvement of the left ventricular ejection fraction in patients 
with ischemic heart disease (3-5), which falls well below the 
expectations towards this new therapeutic approach. These 
disappointing results could be the consequence of the unclear 
underlying mechanism of action of the therapeutic cells which 
may involve various mechanisms such as paracrine and direct 
cell-to-cell effects (6-10). Understanding the mechanisms of 
action could lead to better optimalization of the used proto-
cols. On the other hand, most of the therapeutically added cells 
die in the noxious and aggressive environment of ‘postisch-
emic’ myocardium (11-13). While some experimental evidence 
suggest that the effect is mostly due to apoptotic cells which 
secrete factors that could protect cells after myocardial infarct 
(14), it is reasonable to hypothesize that if more cells survived 
after grafting, then their actions, either paracrine or cell-to-
cell, could be more efficient and, thus, the treatments could be 
more effective. Evidence supporting this concept has already 
been validated using various pretreatment methods, such as 
‘priming’ with growth factors or modifying with Akt (15-18). 
A further possibility to enhance survival could be to prepare 
cells for the oxidative stress present in the reperfused cardiac 
tissue. Oxidative stress induced pathways play a major role in 
the development of ‘postischemic’ injuries in the heart (19-21) 
and these involve poly(ADP-ribose) polymerase (PARP) 
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activation (22,23). PARP is an energy-consuming enzyme 
that functions primarily as a DNA damage sensor in the 
nucleus and catalyzes the cleavage of NAD+ into nicotinamide 
and ADP-ribose, then transfers ADP ribose units to nuclear 
proteins such as histons and transcription factors. As a result 
of this process, the intracellular NAD+ and ATP levels remark-
ably decrease, resulting in cell dysfunction and cell death (24). 
Recent studies have also implicated the importance of mito-
chondrial dysfunction and mitochondrial cell death factors, 
including apoptosis-inducing factors in the process of oxidant-
induced cell death and the potential role of PARP in regulating 
these factors in various cell types including myocardial cells 
(25-28).
Previous studies have demonstrated the direct protec-
tive effect of PARP inhibition of cells or tissues undergoing 
ischemia-reperfusion (I-R) injury (23,29-31). Our aim was 
to assess the potential of PARP inhibitor pretreatment in a 
cell-based therapy setting where the added therapeutic cells 
received the pretreatment. Accordingly, we used a reductionist 
in vitro model of cell-based therapy in myocardial infarct 
where the therapeutically added cells were pretreated with 
PARP inhibitor and we investigated if improved survival of 
the therapeutic cells could enhance the viability of cells under-
going simulated I-R injury.
Materials and methods
Cell culture. H9c2 rat cardiomyoblasts were purchased from 
ATCC (Wesel, Germany). Cells were cultured in high glucose 
(4.5 g/l) DMEM containing 10% fetal bovine serum, 4 mM 
L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin 
at 37˚C in a humidified atmosphere of 5% CO2. Cell culture 
media were changed every 2-3 days and cells were sub-
cultured once they reached 70-80% confluence. Cells between 
passages 7 and 13 were used in the experiments.
Simulated ischemia-reperfusion model. Myocardial I-R was 
simulated in vitro on H9c2 rat cardiomyoblast cell cultures 
based on the method of Cselenyák et al (9) with modifications. 
Briefly, to mimic the ischemic conditions, cells were incubated 
in glucose-free DMEM in an atmosphere of 0.5% O2 and 
99.5% N2 for 160 min on the stage of a confocal microscope 
(PeCon Incubation System, Erbach-Bach, Germany). Glucose 
was replaced with fresh high glucose DMEM and the cells 
were placed in standard cell culture conditions (37˚C, 5% CO2) 
until further experimental actions.
Malondialdehyde measurement. Malondialdehyde (MDA) 
formation was used to quantify the lipid peroxidation in our 
simulated I-R model and was measured as thiobarbituric acid 
reactive material. According to the detection limit of the assay 
protocol 1,000,000 cells were used. Five hours after the start 
of simulated reperfusion 50 µl of the cell culture supernatant 
was added to a reaction mixture consisting of 50 µl of 8.1% 
sodium dodecyl sulfate, 375 µl of 20% acetic acid (pH 3.5), 
and 150 µl of distilled water. The mixture was completed 
with 375 µl of freshly prepared, boiling hot thiobarbituric acid 
(0.8%) and incubated at 95˚C for 1 h. After cooling to room 
temperature, 200 µl supernatant was transferred into 96-well 
microplates and the absorbance was measured at 532 nm (32). 
Malonaldehyde bis(dimethyl acetal), thiobarbituric acid and 
sodium dodecyl sulfate were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
In vitro model of cell based therapy. Based on our previous 
experiments (33), we used H9c2 cells as therapeutic cells 
which were added to the damaged cells 30 min after the start 
of simulated reperfusion and set a simulated ischemia so severe 
that the untreated therapeutic cells were not able to improve 
survival. The optimal time of simulated ischemia was set 
using time lapse video microscopy to follow the changes in the 
fluorescent intensity of calcein-AM/ethidium-homodimer-2 
(EthD) viability staining (Fig. 1A). After ~2 h, rapid decrease 
occurred in the calcein-AM intensity and at the same time the 
intensity of the dead cell indicator EthD increased (Fig. 1B). 
For the experiments we chose an ischemia length of 160 min. 
The used therapeutic cells were divided into 3 experimental 
groups according to their pretreatment protocol lasting 1 h: 
1) control group treated with saline vehicle; 2) 10 µM PJ34 
(PARP inhibitor; Inotek Pharmaceuticals Corp., Beverly, MA, 
USA); 3) 100 µM PJ34. After the pretreatment, the H9c2 cells 
were washed twice with PBS to ensure no PARP inhibitor 
remained, trypsinized, collected by centrifugation and 
20,000 cells were given the appropriate wells of the 12-well 
plate containing 30,000 ‘postischemic’ cells that underwent 
simulated I-R. Cells were co-cultivated for 24 h before further 
flow cytometric, lactate dehydrogenase (LDH) release and 
metabolic activity measurements (Fig. 1C).
Lactate dehydrogenase measurements. We used measure-
ments of LDH release for three reasons: i) to evaluate the I-R 
model; ii) to describe the cytotoxicity and efficacy of PJ34 on 
our H9c2 cells; iii) to compare the cumulated necrosis of cells 
in the experimental groups of our cell-therapy model. In the 
evaluation of the model, 100,000 H9c2 cells were used and 
measured at 24 h after the start of reperfusion. For the evalu-
ation of the PJ34 PARP inhibitor, we measured an untreated 
group and groups pretreated with 10 or 100 µM PJ34. After 
incubation with vehicle or PJ34 for 1 h, 10,000 cells were 
placed in a well and each group was either treated with vehicle 
to evaluate the cytotoxicity of the inhibitor or given 400 µM 
H2O2 for 2 h to check the inhibitor's efficacy. Measurements 
were standardized using untreated cells and cells were lysed 
using 1% Triton X-100 or cell lysis solution to obtain the 
background and the total LDH content. In the third case, the 
LDH level was estimated in cell culture supernatant 24 h after 
reperfusion according to the manufacturer's instructions (LDH 
Cytotoxicity kit I and II; PromoCell, Heidelberg, Germany) 
and differences compared to the vehicle treated group (H9c2) 
were given. The absorbance was taken at 450 and 650 nm and 
the percentage of cytotoxicity was calculated.
Flow cytometric measurements. Flow cytometric analysis was 
performed 24 h after reperfusion (FACSCalibur™; Becton-
Dickinson, Franklin Lakes, NJ, USA). Cells were harvested 
by trypsinization and resuspended in 500 µl PBS containing 
250 nM calcein-AM (ex/em, 494/517 nm; Invitrogen, 
Carlsbad, CA, USA) and 350 nM ethidium-homodimer-2 (ex/
em, 536/624 nm; Invitrogen). Using flow cytometry we could 
distinguish the therapeutically given cells from the ‘postisch-
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emic’ cells on the basis of their Vybrant DiD labeling (ex/em, 
633/665 nm; Molecular Probes, USA) and these cells were 
gated in or out as appropriate for further analysis. Evaluation 
of cell death was performed according to Palma et al (34). 
Briefly, maximally ethidium homodimer-2 positive and slightly 
calcein-AM negative cells were considered necrotic, ethidium 
homodimer-2 negative but calcein-AM positive cells were 
counted as live and a distinct group of cells with intermediate 
staining characteristics was considered as apoptotic (Fig. 2).
Metabolic activity. For the evaluation of the metabolic activity 
in the experimental groups we used PrestoBlue™ cell viability 
reagent (Invitrogen). PrestoBlue is a resazurin-based reagent 
that functions as a cell viability indicator by using the reducing 
power of living cells. Cardiomyoblasts were prepared on a 
12-well plate and therapeutic cells were added after simulated 
I-R as previously described. After 24 h of co-cultivation, the 
culture media was replaced by phenol red free high glucose 
DMEM containing 10% PrestoBlue cell viability reagent. 
Following a further 24 h of incubation, 200 µl cell culture 
supernatant was taken from all samples and added into the 
wells of a 96-well plate. The absorbance was measured at 570 
and 600 nm, according to the manufacturer's description, and 
the 570 nm values were normalized to the 600 nm values.
Statistical analysis. The flow cytometric measurements were 
evaluated using Weasel software (WEHI, Australia). Statistical 
analysis of data was carried out using one-way analysis of vari-
ance with the Newman-Keuls multiple comparison post hoc 
test or the Student's t-test as appropriate. All data are expressed 
as the means ± SEM. A P-value of <0.05 was considered to 
indicate statistically significant differences.
Results
Simulated ischemia-reperfusion protocol. The level of the 
oxidative stress based on MDA assay significantly increased 
in our I-R model (13.70±0.81 µM) compared to untreated cells 
(0.47±0.18 µM) (Fig. 3A). Oxygen glucose deprivation led to 
a significant increase in the LDH levels in the supernatant 
compared to the control conditions (untreated, 0.00±0.81%; 
I-R model, 29.58±6.21%) (Fig. 3B). The PARP inhibitor PJ34 
did not exert any cytotoxic effect in the used concentrations in 
our H9c2 cells and significantly protected these cells against 
H2O2 induced injury in both concentrations (untreated + H2O2, 
35.14±1.01%; 10 µM PJ34 + H2O2, 15.65±0.95%; 100 µM 
PJ34 + H2O2, 15.69±0.54%) (Fig. 3C).
Flow cytometric measurements. Flow cytometric analysis 
of live, apoptotic and necrotic populations of the therapeuti-
cally added cells showed significantly increased survival with 
PARP inhibition (H9c2, 52.02±5.01%; H9c2 + 10 µM PJ34, 
63.38±4.50%; H9c2 + 100 µM PJ34, 64.99±3.47%), while the 
ratio of necrotic cells decreased when PJ34 pretreatment was 
used (H9c2, 37.23±4.40%; H9c2 + 10 µM PJ34, 26.83±3.49%; 
H9c2 + 100 µM PJ34, 24.96±2.43%). No differences were 
found among the ratios of apoptotic cells (H9c2, 10.87±1.12%; 
H9c2 + 10 µM PJ34, 9.22±1.28%; H9c2 + 100 µM PJ34, 
10.18±1.55%) (Fig. 4A).
There was no significant difference between the I-R 
model and the H9c2 treated group regarding live (I-R model, 
36.44±5.05%; H9c2, 42.81±5.11%) and necrotic (I-R model, 
43.64±4.00%; H9c2, 37.29±4.55%) ratios. This was expected 
as the experimental damage was set to acquire such data. 
However, and importantly, the survival of the ‘postischemic’ 
cells was higher when treated with PARP-inhibited therapeutic 
cells (H9c2 + 10 µM PJ34, 52.07±5.80%; H9c2 + 100 µM PJ34, 
Figure 1. Experimental setup. (A) Confocal microscopy images taken before 
and after oxygen glucose deprivation (green, calcein-AM; red, EthD). 
(B) Changes in fluorescent intensity of live/dead staining during simulated 
ischemia. (C) Experimental protocol.
Figure 2. Representative image of the three groups found during the analysis 
of cell survival (green, calcein-AM positive living cells; red, ethidium-
homodimer-2 positive necrotic cells; violet, double positive apoptotic cells).  
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54.95±5.55%) and the ratio of necrotic cells also decreased 
(H9c2 + 10 µM PJ34, 30.18±4.60%; H9c2 + 100 µM PJ34, 
25.52±3.47%). The percentages of apoptotic cells did not show 
a statistically significant difference among the groups (I-R 
model, 19.94±2.75%; H9c2, 20.23±2.62%; H9c2 + 10 µM PJ34, 
17.20±2.42%; H9c2 + 100 µM PJ34, 20.05±3.23%) (Fig. 4B).
Figure 3. Validation of the experimental model. (A) Concentration of the lipid peroxidation product MDA in the supernatant (***P<0.001 mean ± SEM, n=6). 
(B) Ratio of necrotized cells on the basis of LDH assays (**P<0.01 mean ± SEM, n=12); (C) PJ34 cytotoxicity and inhibitor efficacy (***P<0.001 mean ± SEM, n=6).
Figure 4. Results of flow cytometric live/dead analysis. (A) The ratio of living, apoptotic and necrotic therapeutically added cells (*P<0.05 vs. H9c2, **P<0.01 vs. 
H9c2, mean ± SEM, n=18). (B) The ratio of living, apoptotic and necrotic cells in the ‘postischemic’ groups (*P<0.05 vs. H9c2, **P<0.01 vs. H9c2, ###P<0.001 vs. 
I-R model, mean ± SEM, n=18).
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Lactate dehydrogenase cytotoxicity assay. Cellular necrosis 
expressed by LDH release decreased significantly when the 
therapeutic cells were pretreated with the PARP inhibitor. 
Using 10 µM and 100 µM PJ34 the LDH release decreased 
with 6.04±3.61% and 8.68±3.98%, respectively (Fig. 5A).
Metabolic activity. PARP inhibition significantly enhanced 
the overall metabolic activity of the cells when therapeutic 
cells were treated with 10 µM PJ34 compared to untreated 
H9c2 (H9c2, 0.64±0.04%; 10 µM PJ34, 0.71±0.04%; arbitrary 
units). There was only a nonsignificant trend of such increase 
when a 100 µM concentration PJ34-treated cardiomyoblasts 
were used (0.68±0.04%) (Fig. 5B).
Discussion
Herein we report that the pretreatment of therapeutic cells 
improves their survival and subsequently increases the 
viability of the damaged cardiomyoblasts in an in vitro reduc-
tionist model of cell-based therapy in myocardial infarct. First, 
we evaluated our experimental in vitro model for oxidative 
stress, necrotic properties and we checked the cytotoxicity and 
efficacy of the used PARP inhibitor. We found that following 
oxygen and glucose deprivation, the MDA levels are increased, 
as it can be observed in in vivo ischemic conditions. According 
to our measurements on cell membrane integrity based on 
LDH level, the simulated ischemia is followed by significant 
membrane damage. Thus the applied model properly simulates 
the I-R injury. The earlier data on the PARP inhibitor were 
confirmed regarding its cytotoxicity and efficacy in the used 
concentrations (29). This measurement also indicates that our 
in vitro simulated ischemia model caused damage similar to a 
400 µM H2O2 treatment for 2 h. The timing of the cell addition 
was partly chosen based on the literature that suggests non-
immediate delivery of cells (35) and partly on our own pilot 
experiments that also suggested better efficacy if cells were 
given 30 min after the start of reperfusion (data not shown).
Using flow cytometry we showed that PARP inhibition of 
the therapeutic cells could improve the viability of the ‘post-
ischemic’ cells. The mechanism of this beneficial effect seems 
to be connected to the increased ratio of surviving therapeutic 
cells. It appears, therefore, that the therapeutic cells with PJ34 
pretreatment could help damaged cells to survive. Untreated 
therapeutic cells had no significant effect on this cell popu-
lation. Imaging a real myocardial infarct it may mean that 
areas with bigger oxidative damage could also be saved 
with such pretreated therapeutic cells. Regarding the exact 
mechanism of the therapeutic cells we assume based on our 
earlier observations (9,33) and on the results of others (8,36), 
that this beneficial effect could be related partly to cell-to-cell 
connections and partly to paracrine factors released from the 
therapeutic cells.
If we consider the possible mechanisms related to the 
improved survival of therapeutic cells we must remember 
that reactive oxygen species are believed to play a key role 
in the myocardial I-R injury and myocardial cell death in 
I-R is mediated mainly by necrosis and the mechanism is 
based on the oxidative stress-induced activation of PARP 
(37). It is important to realize at this point that the PARP 
inhibitor treatment occurred before adding the therapeutic 
cells to the damaged ones, therefore these latter cells did 
not receive any pretreatment. The protective effect of PJ34 
is extended beyond the end of the treatment and pharmaco-
kinetic data indicate that the prolonged effect of PJ34 is not 
related to the continued presence of the inhibitor, but it may 
be related to the permanent interruption of positive-feedback 
cycles of injury. Earlier studies have demonstrated that 
PARP inhibitors block positive-feedback cycles of adhesion-
receptor expression and mononuclear cell infiltration, as well 
as intracellular oxidant generation (24). A possible concern 
could be the potential genotoxic nature of PARP inhibitors as 
these block the DNA-repair mechanisms. Results from earlier 
studies disprove this as one study showed that the inhibition 
of poly(ADP-ribosyl)ation did not particularly modify geno-
toxicity (38) while another, using bacterial reverse mutation 
test, in vitro chromosomal aberration test and bone marrow 
micronucleus test concluded that PARP inhibition did not 
possess genotoxic activity (39).
In our subsequent experiments, the effect of PARP inhibi-
tion pretreatment was examined using LDH and PrestoBlue 
measurements. These two methods reflect the necrosis 
and metabolic activity of both cell populations after 24 h, 
respectively. LDH values significantly decreased with both 
applied concentrations of PJ34. Pretreatment with 10 µM 
PJ34 significantly increased the metabolic activity in the 
cell culture compared to untreated H9c2, but in the case of 
100 µM PJ34 we saw only a non-significant trend towards the 
increased value. Blocking PARP activation as much as it is 
possible should lead, at least in theory, to better protection. 
The higher concentration in our experiments, however, could 
not improve the beneficial effect further or in the case of 
PrestoBlue it was only a non-significant increase. Thus, we 
suspect that 10 µM PJ34 fully blocks the PARP enzyme in 
H9c2 cells after 1 h. The results that the higher concentration 
of PJ34 did not significantly improve the metabolic activity of 
Figure 5. Cytotoxicity and viability measurements. (A) Decrease in LDH release 
on an inverted scale (*P<0.05, **P<0.01 mean ± SEM, n=7). (B) Metabolic 
activity measured by PrestoBlue reagent (*P<0.05 mean ± SEM, n=8).
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‘postischemic’ cells may reflect that higher concentration of 
PARP inhibitors could cause metabolic suppression, but this 
hypothesis warrants further investigations. As a limitation to 
the interpretation of these measurements, it must be realized 
that the combined LDH levels and metabolic activities of the 
two cell populations were measured. However, as these factors 
are frequently used to reflect the viability of cell groups we 
believe that the improved combined values provide valuable 
data to our study and further strengthen our findings.
There are some other limitations to our study as well. First, 
the demonstrated protocol is an in vitro approach to the much 
more complex issue of stem cell therapy in myocardial infarct, 
with all the advantages and disadvantages of such a model. 
Obviously, it cannot reflect the complex (e.g. immunological) 
events taking place during and after myocardial infarct but 
the parameters (time of the ischemia and reperfusion, the 
temperature and the O2 concentration) can easily be controlled 
and the effects of the added cells on the ‘postischemic’ cells 
can be quantified. The 24 h co-cultivation time period was 
chosen based on preliminary experiments as this time was 
found to suffice for the attachment of the newly added cells 
but was not enough for proliferation. Second, we used H9c2 
cells as a model for cardiac muscle and although the cell 
line is frequently used in similar experiments they resemble 
skeletal muscle cells just as much as cardiac muscle (40,41). 
Thus, conclusions drawn from results obtained from them 
should be considered cautiously. Another concern could be the 
fact that we used H9c2 cells as therapeutic cells. Our earlier 
experimental evidence showed that healthy H9c2 cells could 
save their oxidatively damaged neighbors from delayed death 
(33). Furthermore, since we obtained similar effectiveness 
with stem cells and H9c2 cells in that model, it reflects that 
multipotency of the grafted cells is not required for this type 
of rescue effect, widening the possible sources for cell therapy.
Our data are in line with other observations on pretreat-
ments in the literature. Yao et al (15) transplanted mesenchymal 
stem cells pretreated with lipopolysaccharide into an in vivo 
rat model. They found better vascularisation, lower fibrosis 
in the myocardium, and the viability of the therapeutic cells 
improved. Hahn et al (16) used a growth factor combination 
for pretreatment and checked the survival of the cells after 
0.5% hypoxia for 30 h. They found a 20% increase in trypan 
blue exclusion. This effect is quantitatively similar to the 
effect of our PJ34 inhibition achieved in the H2O2 protocol. 
Mouse BMSCs were pretreated with H2O2 for 30 min in the 
Kubo et al (18) model. The production of vascular endothelial 
growth factor was increased and the differentiation towards 
endothelial cells was promoted. Mangi et al (17) pretreated 
therapeutic cells with retroviral manipulation for overex-
pressing Akt1 which restored the myocardium more effectively 
than the control cells. Of note, however, we believe that our 
study presents the first quantitative viability data on the effect 
of therapeutic cell pretreatment on the ‘postischemic’ cells.
In conclusion, addition of PARP-inhibited cells to severely 
injured cardiomyoblasts can improve survival and decrease 
cellular necrosis in an in vitro cell therapy model for I-R 
injury. This approach, if confirmed in experiments using 
human derived cells and in in vivo studies, could lead to a 
better efficacy of cell-based therapies with a relatively simple 
and economical pretreatment step.
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